OTC · BTTX
Healthcare · Biotechnology
$0.00
Up+$0.00 (+0.00%)
Updated Aug 23, 2026, 6:10 PM
SID Score
3.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
BTTX does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning BTTX.
BTTX research
Company profile and research snapshot.
BETTER THERAPEUTICS INC
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 10, 2023 | Lake Street | Buy | — |
| Aug 10, 2023 | Chardan Capital | Buy | — |
| Apr 14, 2023 | Lake Street | Buy | — |
| Mar 31, 2023 | Chardan Capital | Buy | — |
| Nov 15, 2022 | Chardan Capital | Buy | — |
No generated briefing is available yet.
Zacks Investment Research · Feb 22, 2024
Better Therapeutics' (BTTX) novel CBT platform attains the FDA's breakthrough device designation to improve patient care in the treatment of liver and metabolic diseases.
Zacks Investment Research · Oct 10, 2023
Alnylam's (ALNY) label expansion-seeking application for Onpattro, to treat transthyretin-mediated amyloidosis with cardiomyopathy, gets the FDA's CRL on the grounds of insufficient data. The stock falls 5%.
Zacks Investment Research · Oct 10, 2023
Jasper (JSPR) announces the FDA clearance to begin the clinical study of briquilimab for chronic spontaneous urticaria. The stock of the company rises 16%.
Zacks Investment Research · Oct 6, 2023
Lineage (LCTX) rises 10% on positive imaging analyses results from the phase I/IIa study of OpRegen in patients with geographic atrophy secondary to age-related macular degeneration.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BTTX.
No results
No recent SID articles mention BTTX.
